Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to Biktarvy in virologically suppressed HIV-1-infected adults ≥65 years at risk of polypharmacy
2019-002843-81Phase 4Active
- Sponsor
- Institut de Médecine et d'Epidémiologie Appliquée
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bictegravir + emtricitabine + tenofovir alafenamide in Human immunodeficiency virus infection type 1, sponsored by Institut de Médecine et d'Epidémiologie Appliquée. Primary endpoint: Virological failure at week 24. Started Aug 2019; status: active.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2019-002843-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002843-81.